Amplia Reports First Patient Dosing in Phase 2A Accent Trial
Posted: 19 January 2024 Amplia Therapeutics Limited is pleased to announce that the first patient in the Phase 2a portion of the ACCENT trial has begun dosing. The ACCENT trial is examining the combination of Amplia’s best-in-class FAK…
A $268 million investment to support innovative research projects
Posted: 22 December 2023 With a focus on innovation and creativity, NHMRC’s Ideas Grant scheme enables researchers at all career stages to work together to address specific research questions to advance within their field for the improvement of…
i-body®-ENABLED BREAKTHROUGH IN MALARIA TREATMENT
Posted: 22 December 2023 In collaboration with La Trobe University, AdAlta has discovered an i-body® believed to be the first ever antibody-like molecule capable of high potency inhibition of malaria parasite invasion of red blood cells and liver…
$1.7 million funding boosts skin disease research at the Doherty Institute
Posted: 22 December 2023 University of Melbourne’s Professor Laura Mackay, Laboratory Head and Immunology Theme Leader at the Doherty Institute, and the University of Melbourne’s Associate Professor Sarah Dunstan, Principal Research Fellow in Infectious Diseases and a Lead of the…
App to boost ear health and mental wellbeing in Indigenous communities
Posted: 22 December 2023 An app that makes it fun for Aboriginal children to enhance their hearing and mental health, developed by a Monash University researcher in collaboration with Curtin University and Ear Science Institute Australia, has received…
Adherium Delivers First Order of Hailie Smart Inhaler Sensors to US Intermountain Health
Posted: 22 December 2023 Adherium Limited (ASX:ADR) a leader in digital health technologies has delivered the first purchase order agreement of 1,750 of its next generation Hailie® Smartinhaler® sensors to major US hospital system, Intermountain Health. This sale…
Preparing for Growth: Biointelect Appoints New CEO
Posted: 22 December 2023 Biointelect is delighted to wrap up 2023 by announcing the appointment of Leah Goodman as Chief Executive Officer. Leah will lead the organisation through its next exciting period of strategic growth cementing our unique…
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Posted: 22 December 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces constructive feedback has been received from the Paul-Ehrlich-Institut (“PEI”), a…
Positive DEP® docetaxel Phase 2 results
Posted: 20 December 2023 Starpharma today announces positive final results from the completed Phase 2 clinical program of DEP® docetaxel. The clinical program included a monotherapy arm and two combination arms. The Phase 2 trial objectives were met, with endpoints…
Neuren Ph2 trial shows significant improvements in Phelan-McDermid
Posted: 18 December 2023 Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS). Significant improvement was observed by both clinicians and caregivers from treatment, across…
Atmo Biosciences achieves patient recruitment target for dysmotility pivotal clinical study
Posted: 14 December 2023 More than 200 patients recruited in multi-site clinical trial to support a submission for initial U.S. regulatory clearance around the use of Atmo’s gas-sensing capsule to assess gastrointestinal motility disorders. Atmo Biosciences, a company…
Newborn medicine project celebrated by NHMRC as one of the best
Posted: 14 December 2023 The team behind a Murdoch Children’s Research Institute (MCRI) led project has been celebrated for their work in newborn medicine, aiming to improve the health outcomes of preterm and sick babies. Professor Lex Doyle and…
